Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JP4612924B2 - Cytokine regulator - Google Patents
[go: Go Back, main page]

JP4612924B2 - Cytokine regulator - Google Patents

Cytokine regulator Download PDF

Info

Publication number
JP4612924B2
JP4612924B2 JP27289399A JP27289399A JP4612924B2 JP 4612924 B2 JP4612924 B2 JP 4612924B2 JP 27289399 A JP27289399 A JP 27289399A JP 27289399 A JP27289399 A JP 27289399A JP 4612924 B2 JP4612924 B2 JP 4612924B2
Authority
JP
Japan
Prior art keywords
tgf
extract
group
administration
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP27289399A
Other languages
Japanese (ja)
Other versions
JP2001058950A (en
Inventor
文郎 米田
静子 村岡
美保 森口
伸嘉 則貞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujimoto Pharmaceutical Corp
Original Assignee
Fujimoto Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujimoto Pharmaceutical Corp filed Critical Fujimoto Pharmaceutical Corp
Priority to JP27289399A priority Critical patent/JP4612924B2/en
Publication of JP2001058950A publication Critical patent/JP2001058950A/en
Application granted granted Critical
Publication of JP4612924B2 publication Critical patent/JP4612924B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Description

【0001】
【産業上の利用分野】
本発明は、ワクシニアウイルス接種家兎皮膚抽出液を有効成分とするサイトカイン調節剤を提供するものである。
【0002】
【従来の技術】
サイトカインは、免疫担当細胞をはじめとする種々の細胞から産生され、極めて微量で細胞間相互作用に不可欠の生物活性を有する糖蛋白であり、リンパ球から産生されるサイトカインはリンフォカイン、単球・マクロファージ系細胞から産生されるサイトカインはモノカインとも称される。サイトカインの生物活性には、正の調節機構と負の調節機構の両方が存在し、正常状態では調節機構がバランスよく作動し相互にネットワークを組み生体の恒常性を担っている。
【0003】
しかし、このバランスが崩れると、サイトカイン産生異常が出現したり、または種々の疾患の形成、増悪の原因となる。例えば、産生された腫瘍壊死因子(TNF−α)に対する負の調節機構(制御機構)が十分機能しない場合、TNF−αはサイトカインネットワークを介して、インターロイキン−1(IL−1)、インターロイキン−6(IL−6)、インターロイキン−8(IL−8)等のさまざまな他の炎症性サイトカインの産生を促進し、産生されたサイントカインが再びTNF−αの産生を促進するといった連鎖反応により、炎症の悪循環を生じさせ、ついには骨、軟骨等での組織が破壊され、自己免疫疾患である関節リウマチ等につながるといわれている。
【0004】
【発明が解決しようとする課題】
現在、さまざまな疾患において、病態の形成、増悪及び疼痛に関与するサイトカインが判明してきており、そのため、サイトカインを疾患の診断や治療の判定に応用する研究や、更に進んで、過剰なサイトカインの産生またはその活性の抑制、不足・欠乏サイトカインの補充、産生促進等を新たな治療法とする研究が盛んである。
【0005】
種々のサイトカインのうち、トランスフォーミンググロウスファクター−β(TGF−β)は、線維芽細胞の増殖因子として見出されたサイトカインであるが、遺伝子工学的に造り出されたTGF−β欠損マウスにおいて、多臓器における多発性炎症または多臓器不全が発症すること(ネイチャー(Nature),359:693,1992)、及び、骨芽細胞の増殖、細胞外基質合成基質分泌の促進、基質分解酵素産生の阻害、各種組織の肉芽形成、線維化促進作用及び細胞分化作用に基づく創傷または熱傷等の組織損傷修復作用、接着因子の発現促進作用に基づく網膜剥離に対する治療作用、過剰な免疫反応の抑制作用、Tリンパ球細胞群をTh細胞群へシフトさせる作用等が観察されている。更に、最近では、重症動脈硬化症では血清中の活性型TGF−βレベルの著しい低下が認められ(ネイチャー メディシン(Nature Medicine),:74,1995)、動脈硬化症の形成、増悪にもTGF−βレベルの低下が関与していると推察されている。このTGF−βの生物活性の作用機序としては、TGF−βが上皮由来の細胞、血管内皮細胞、リンパ球、その他の造血系細胞に対して強い細胞増殖抑制作用を示すること、これら細胞由来のサイトカインの産生を抑制することが重要視されている。
【0006】
また、インターロイキン−10(IL−10)は、免疫担当細胞であるTリンパ球のThとThからなる細胞群のうち、おもにTh細胞群から産生されるサイトカインで、腸管系における免疫機構の制御作用、CD8細胞障害性T細胞、抗体産生細胞、肥満細胞に対する促進的作用、Th細胞やマクロファージに対する抑制的作用、Th細胞由来サイトカインであるインターフェロン−γ(IFN−γ)及びマクロファージ由来のサイトカインであるTNF−α、IL−1、IL−6等の産生を抑制することが知られている。これらTNF−αとIL−1は、その産生機序または生物活性がよく重複しあうサイトカインとして知られており、また、TNF−α、IL−1、IL−6は、ヒトの潰瘍性大腸炎やクローン病等の炎症性腸疾患、穿孔性腹膜炎、グラム陰性菌等による敗血症からの予後不良等の疾患の形成、増悪に深く関与しているといわれている。そして、ヒトの潰瘍性大腸炎やクローン病ではTNF−α、IL−1、IL−6の産生を抑制するIL−10の血清中レベルが有意に低下していること(臨床免疫27,16:97,1995)、IL−10遺伝子欠損マウスでは自己免疫性腸疾患が確実に発症すること(セル(Cell),75:263,1993)、IL−10がこれらサイトカインに起因した疼痛をおさえること(ブリティッシュ ジャーナル オブ ファーマコロジー(Brit.J.Pharmacol.),115:684,1995)等の報告から、IL−10産生の促進は、これらマクロファージ系細胞及びTh細胞から産生されるサイトカインの過剰が誘因となって、発症、増悪経過をたどる疾患に有用であることが明らかにされている。
【0007】
【課題を解決するための手段】
本発明者らは、有効成分名がワクシニアウイルス接種家兎炎症皮膚抽出液と称される医薬品原薬に、上皮由来細胞、血管内皮細胞、リンパ球、その他の造血系細胞に対する強い細胞増殖抑制作用、これら細胞に由来する炎症性または細胞障害性等のサイトカインの産生を抑制するTGF−βの産生を促進し、また、マクロファージ系細胞またはTh細胞由来のサイトカインの産生あるいは活性を抑制する作用をもつIL−10の産生を促進し、IFN−γ及びTNF−αの産生を抑制する活性が存在することを知見し、本発明を完成した。
【0008】
ワクシニアウイルス接種家兎炎症皮膚抽出液は、例えば医療薬日本医薬品集1997年10月版第1710頁に記載されている既知の物質であり、これを有効成分とした製剤は、免疫調整、抗アレルギー、鎮痛および鎮静剤、特にストレス状態にある神経組織に対し特異的に作用する薬剤として、その含有量は力価を示す「単位」で表されるか、または当該「単位」と実質的に同等とされている「ノイロトロピン単位」で表され、医療用薬剤として市販されている(以下、「単位」に統一して記す)。しかし、これまで、サイトカインであるTGF−β、IL−10、IFN−γおよびTNF−αに対する調節作用は全く知られていなかった。
【0009】
本発明にかかるワクシニアウイルス接種家兎炎症皮膚抽出液の投与量は、疾患の種類や患者個人の感受性、調節すべきサイトカインのレベルによって異なるが、1〜60単位/日の範囲で増減が可能であり、また、投与に際しては、適した有機または無機の固体または液体賦形剤のような医薬用担体と混合して投与することができる。通常は3〜32単位/日、好ましくは3.6〜16単位/日を、1日に1回または2〜4回に分けて、静脈内投与、皮下投与、筋肉内投与または経口投与する。
【0010】
以下に実施例を示して本発明を詳細に説明するが、これらの実施例は本発明の範囲を限定するものではない。尚、特に説明がない限り、「抽出液」は本発明のワクシニアウイルス接種家兎炎症皮膚抽出液を意味する。
【0011】
【実施例1】
8〜15週令の(C57BL/6 X DBA/2)F雌マウスに、本発明のワクシニアウイルス接種家兎炎症皮膚抽出液(抽出液) 12.5単位/kgを単回腹腔内投与した場合と、3日間連日腹腔内投与した場合の、投与後24時間目にマウスを脱血し血清を採取した。対照群のマウスには、投与した抽出液と同一容量の注射用生理食塩液を投与した。各群3匹のマウス使用。血清を採取したマウスと同一マウスより脾臓を採取し、直ちに定法により全RNAを抽出精製し−80℃に保存し、逆転写反応−ポリメラーゼチェインリアクション(RT−PCR)用サンプルとした。各々のマウス脾臓RNA1μgにTGF−β遺伝子特異的下流プライマーを加え、逆転写酵素を作用させてcDNAを合成した後、上流プライマーを更に添加し、耐熱性DNA合成酵素を用いてcDNAを増幅した。各サンプルのcDNAを2%寒天ゲル電気泳動により分画し、525塩基対のバンドの濃度をデンシトメーターにより測定した。同様に、各サンプルのRNAより内部標準としてグリセルアルデヒド−3−リン酸脱水素酵素(G3PDH)遺伝子についても逆転写反応によりcDNAを合成後、cDNAを増幅した。寒天ゲル電気泳動により分画した983塩基対のG3PDHバンドの濃度を、デンシトメーターにより測定した後、各サンプルにつきTGF−βバンドとG3PDHバンドの濃度比を算出した。
【0012】
その結果として、2%寒天ゲル電気泳動により分画した各サンプルのTGF−βバンドは抽出液投与群のcDNA産物のバンドの方が、対照群に比較し濃いバンドを示し、抽出液投与によりTGF−β遺伝子転写が促進された。デンシトメーター測定によるTGF−βバンドとG3PDHバンドの濃度比の平均値は、抽出液投与群は約0.9であり、対照群は約0.7で、抽出液投与群の平均値が対照群の平均値より高い値を示した(第1図)。異なる日時に、再度同様の抽出液腹腔投与実験を繰り返し、ワクシニアウイルス接種家兎炎症皮膚抽出液腹腔内投与が、TGF−β遺伝子転写を統計学的に有意(p〈0.01)に促進することを確認した(第2図)。
【0013】
【図1】
【0014】
【図2】
【0015】
【実施例2】
8〜15週令の(C57BL/6 X DBA/2)F雌マウス2匹に、本発明のワクシニアウイルス接種家兎炎症皮膚抽出液(抽出液)12.5単位/kgを、1日1回3日間連日腹腔内投与した。24時間後に脾臓を採取し、細胞を48時間培養した。対照群のマウス2匹には、投与した抽出液と同一容量の注射用生理食塩液を同様に投与した。培養上清を回収し、TGF−βの生物活性をミンク肺線維芽細胞の増殖抑制活性として、1匹よりのサンプルを2回定量し、その平均値を算出した。あるいは脾臓を採取後、脾細胞を単離し、コンカナバリンAと共に24時間培養後、培養上清を採取した。脾細胞培養上清中の活性型TGF−β蛋白量を、サンドイッチ固相酵素免疫(ELISA)測定法により決定した。
【0016】
抽出液投与により、TGF−βの遺伝子転写促進ばかりでなく、TGF−βの蛋白産生も促進されることが確認された。なお本生物活性測定法は、TGF−β、TGF−β、TGF−βの全TGF−β活性を検出するものであるので、TGF−βばかりでなく抽出液投与のTGF−β、TGF−β産生への影響も推定できることを意味する。生物活性とTGF−β蛋白量との相関性を示す検量線は遺伝子組み換え型ヒトTGF−βを用いて作成した。また活性型TGF−βの測定には、培養上清をそのままサンプルとして用い、全TGF−βの測定は、培養上清を塩酸で処理して潜在型TGF−βを活性型に変換させて行った。本実験の抽出液投与群では、活性型TGF−βは 907,7pg/ml、全TGF−βは 1226.4 pg/mlであったのに対し、対照群では各々135.5 pg/ml、639.6 pg/mlであった(第3図)。このように抽出液投与は、脾細胞よりの活性型及び潜在型の両方のTGF−β産生を促進した。
【0017】
【図3】
【0018】
【実施例3】
8〜15週令の(C57BL/6 X DBA/2)F雌マウスに、本発明のワクシニアウイルス接種家兎炎症皮膚抽出液(抽出液)25単位/kgを腹腔内に1回注射するのとほぼ同時に、コンカナバリンA6.25mg/kgあるいは注射用生理食塩液を皮内注射した。投与後3日目に各マウスより血液を採取し、血清を分離して被検サンプルとした。サンドイッチELISA法を用い、検量線の作成には遺伝子組み換え型ヒトTGF−βを使用して血清中の活性型TGF−β蛋白量を測定した結果、コンカナバリンAを投与されなかった群では、抽出液投与群の血清中の活性型TGF−βは8.76ng/ml、対照群では7.12ng/mlであり、コンカナバリンA投与群では、抽出液投与マウス血清中の活性型TGF−βは7.86ng/ml、対照群では7.05ng/mlであった(第4図)。このように抽出液投与により、コンカナバリンA同時投与の有無に係わらず、血清TGF−βレベルが統計学的に有意に上昇した(p〈0.05)。また、コンカナバリンA同時投与は、血清中のTGF−βレベルには影響を及ぼさなかった。
【0019】
【図4】
【0020】
【実施例4】
8〜15週令の(C57BL/6 X DBA/2)F雌マウスに、本発明のワクシニアウイルス接種家兎炎症皮膚抽出液(抽出液)12.5単位/kgを1日1回3日間連続腹腔内投与し、24時間後に脾臓を採取し、直ちに定法により全RNAを抽出精製し、−80℃に保存後、RT−PCRのサンプルとした。対照群のマウスには、抽出液と同一容量の注射用生理食塩液を投与した。各群3匹のマウスを使用。各々のマウス脾臓RNA1μgにIL−10遺伝子特異的下流プライマーを加え、逆転写酵素を作用させてcDNAを合成した後、上流プライマーを更に添加し耐熱性DNA合成酵素を用いてcDNAを増幅した。同様に、各サンプルの全RNAより内部標準としてG3PDH遺伝子についても、逆転写反応によりcDNAを合成した後、cDNAを増幅した。各サンプルのcDNAを2%寒天ゲル電気泳動により分画し、IL−10の421 塩基対バンドの濃度をデンシトメーターにより測定した。IL−10及びG3PDHのRT−PCR反応後のcDNA産物の2%寒天ゲル電気泳動写真で、抽出液投与群(レーン4、5、6)のcDNA産物の方が、対照群(レーン1、2、3)より濃いバンドを示した。デンシトメーターによりバンド濃度を測定した後、各サンプルにつきIL−10バンドとG3PDHバンドの濃度を比較した結果、対照群のバンド濃度比平均値を1.0としたとき、抽出液投与群の平均値は2.62で、抽出液投与により、IL−10遺伝子転写が有意(p〈0.01)に促進されていた(第5図)。
【0021】
【図5】
【0022】
【実施例5】
本発明のワクシニアウイルス接種家兎炎症皮膚抽出液(抽出液) 12.5単位/kg単回投与によるIL−10遺伝子転写促進確認実験。
各群2匹のマウスを用いて、投与回数を単回投与とした以外は実施例4の実験と同様の操作にて、脾臓mRNA1μgよりIL−10遺伝子についてRT−PCRを行い、遺伝子転写レベルを生理食塩液対照群と比較した結果、無処置群のIL−10とG3PDHバンド濃度比を1.0としたとき、生理食塩液投与群1.31、抽出液投与群2.29で、3回投与に比べて程度は低かったが、単回投与でもIL−10遺伝子転写促進傾向が認められた(第6図)。
【0023】
【図6】
【0024】
【実施例6】
本発明のワクシニアウイルス接種家兎炎症皮膚抽出液(抽出液)10、25、50単位/kgを(C57BL/6 X DBA/2)F雌マウスに、3日間に5回腹腔内投与後、16時間後に脾臓を採取して、脾細胞を単離し、コンカナバリンA 3.0μg/ml存在下で43時間培養し、培養上清中のIL−10をサンドイッチELISA法により定量した。1群5匹使用。検量線の作成には、遺伝子組み換え型マウスIL−10を用いた。抽出液投与群の脾細胞培養上清中に含まれるIL−10蛋白量は、10単位/kg投与群で129.0pg/ml、25単位/kg投与群で131.1pg/ml、50単位/kg投与群で163.6pg/mlであり、抽出液投与のいずれの群でも脾細胞培養上清中のIL−10蛋白濃度が、無処置群107.5pg/ml、あるいは注射用生理食塩液投与群112.3pg/mlのIL−10蛋白濃度に比較し、有意(p〈0.05、あるいはp〈0.01)に上昇した(第7図)。
【0025】
【図7】
【0026】
【実施例7】
(C57BL/6 X DBA/2)F雌マウスに、本発明のワクシニアウイルス接種家兎炎症皮膚抽出液(抽出液)6.25、12.5単位/kgを、1日1回3日間連続腹腔内投与した。対照群のマウスには注射用生理食塩液、また抑制陽性対照群としてデキサメタゾン2mg/kg/回を同様に投与した。最後の投与より約24時間目に脾臓を採取し、脾細胞をコンカナバリンA2.5μg/ml存在下で24時間培養し、培養上清中のIFN−γをサンドイッチELISA法により定量した。検量線の作成には、遺伝子組み換え型マウスIFN−γを用いた。抽出液投与は用量依存的にマウス脾細胞のIFN−γ産生量を減少させ、12.5単位/kgで、デキサメタゾン投与群の1.78ng/mlと同程度の1.94ng/mlまで、IFN−γ産生量を抑制した(第8図)。
【0027】
【図8】
【0028】
【実施例8】
(C57BL/6 X DBA/2)F雌マウスに、本発明のワクシニアウイルス接種家兎炎症皮膚抽出液(抽出液)12.5単位/kgを、1日1回3日間連続腹腔内投与した。対照群のマウスには注射用生理食塩液、また抑制陽性対照群としてデキサメタゾン2mg/kgを同様に投与した。最後の投与より約24時間目に脾臓を採取し、脾細胞を大腸菌由来エンドトキシン(E.coli 026:B6)10/μg/ml存在下で2時間培養し、培養上清中のTNF−αをサンドイッチELISA法により定量した。検量線の作成には、遺伝子組み換え型マウスTNF−αを用いた。抽出液投与群での脾細胞のTNF−α産生は、デキサメタゾン投与群と同程度まで抑制された(第9図)。
【0029】
【図9】
【図面の簡単な説明】
【図1】実施例1におけるRT−PCR反応後のTGF−β及びG3PDHのcDNAの電気泳動後のバンドの濃度比を示すグラフである。
【図2】実施例1と同様の実験を異なる日時に行った実験で、TGF−βとG3PDHの電気泳動後のバンドの濃度比を示すグラフである。
【図3】実施例2におけるマウスの脾細胞培養上清中の活性型TGF−β活性及び全TGF−β活性を示すグラフである。
【図4】実施例3におけるサンドイッチELISA法により測定したマウスの血清中の活性型TGF−βを測定した結果を示すグラフである。
【図5】実施例4におけるRT−PCR反応後のIL−10及びG3PDHのcDNAの電気泳動後のバンドの濃度比を示すグラフである。
【図6】実施例4と同様の実験を異なる日時に行った実験で、IL−10とG3PDHバンドの電気泳動後のバンドの濃度比を示すグラフである。
【図7】実施例6におけるマウスの脾細胞のコンカナバリンA刺激培養上清中のIL−10蛋白量をサンドイッチELISA法により測定した結果を示すグラフである。
【図8】実施例7におけるマウス脾細胞のコンカナバリンA刺激培養上清中のIFN−γ濃度をサンドイッチELISA法測定により測定した結果を示すグラフである。
【図9】実施例8におけるマウス脾細胞の大腸菌由来エンドトキシン刺激培養上清中のTNF−α濃度をサンドイッチELISA法測定により測定した結果を示すグラフである。
[0001]
[Industrial application fields]
The present invention provides a cytokine regulatory agent comprising a rabbit skin inoculated with vaccinia virus as an active ingredient.
[0002]
[Prior art]
Cytokines are glycoproteins that are produced from various cells including immunocompetent cells and have a very small amount of biological activity that is indispensable for cell-cell interactions. Cytokines produced from lymphocytes are lymphokines, monocytes, and macrophages. Cytokines produced from cell lines are also called monokines. There are both a positive regulatory mechanism and a negative regulatory mechanism in the biological activity of cytokines. Under normal conditions, the regulatory mechanisms operate in a well-balanced manner and form a network with each other, and are responsible for homeostasis.
[0003]
However, when this balance is lost, abnormal cytokine production may occur, or various diseases may be formed or worsened. For example, when the negative regulatory mechanism (control mechanism) for the produced tumor necrosis factor (TNF-α) does not function sufficiently, TNF-α is interleukin-1 (IL-1), interleukin via a cytokine network. Chain reaction in which the production of various other inflammatory cytokines such as IL-6 (IL-6) and interleukin-8 (IL-8) is promoted, and the produced signokine promotes the production of TNF-α again. It is said that this causes a vicious cycle of inflammation and eventually destroys tissues such as bone and cartilage, leading to rheumatoid arthritis, which is an autoimmune disease.
[0004]
[Problems to be solved by the invention]
At present, cytokines involved in pathogenesis, exacerbation, and pain have been identified in various diseases. Therefore, research to apply cytokines to diagnosis and treatment of diseases, and further production of excess cytokines In addition, active research is being conducted on the suppression of the activity, supplementation of deficient / deficient cytokines, promotion of production, and the like.
[0005]
Among various cytokines, transforming growth factor-β (TGF-β) is a cytokine found as a growth factor for fibroblasts, but in genetically engineered TGF-β 1- deficient mice. Multiple inflammation in multiple organs or multiple organ failure (Nature, 359 : 693, 1992), and osteoblast proliferation, promotion of extracellular matrix synthesis substrate secretion, production of substrate degrading enzymes Inhibition, granulation of various tissues, fibrosis promotion action and tissue damage repair action such as wound or burn based on cell differentiation action, therapeutic action against retinal detachment based on adhesion factor expression promotion action, suppression action of excessive immune response, The effect of shifting the T lymphocyte cell group to the Th 2 cell group has been observed. Further, recently, significant reduction of active TGF-beta levels in the serum was observed in the severe arteriosclerosis (Nature Medicine (Nature Medicine), 1: 74,1995 ), the formation of arteriosclerosis, even exacerbation TGF It is speculated that a decrease in -β level is involved. As the mechanism of action of the biological activity of TGF-β, TGF-β exhibits a strong cell growth inhibitory action on epithelial cells, vascular endothelial cells, lymphocytes, and other hematopoietic cells. It is important to suppress the production of cytokines derived therefrom.
[0006]
Interleukin-10 (IL-10) is a cytokine produced mainly from the Th 2 cell group among the cell group consisting of Th 1 and Th 2 of T lymphocytes which are immunocompetent cells. Regulatory action of the mechanism, CD8 + cytotoxic T cell, antibody producing cell, promoting action on mast cell, inhibitory action on Th 1 cell and macrophage, Th 1 cell-derived cytokine interferon-γ (IFN-γ) and It is known to suppress the production of macrophage-derived cytokines such as TNF-α, IL-1, and IL-6. These TNF-α and IL-1 are known as cytokines whose production mechanism or biological activity overlaps well, and TNF-α, IL-1, and IL-6 are human ulcerative colitis. It is said to be deeply involved in the formation and exacerbation of diseases such as inflammatory bowel diseases such as Crohn's disease, perforated peritonitis, and poor prognosis from sepsis due to Gram-negative bacteria. In human ulcerative colitis and Crohn's disease, the serum level of IL-10 that suppresses the production of TNF-α, IL-1, and IL-6 is significantly reduced ( clinical immunity , 27 , 16 : 97, 1995), IL-10 gene-deficient mice are sure to develop autoimmune bowel disease (Cell, 75 : 263, 1993), and IL-10 suppresses pain caused by these cytokines. (Brit. J. Pharmacol., 115 : 684, 1995) and the like, the promotion of IL-10 production is due to the excess of cytokines produced from these macrophage cells and Th 1 cells. It has been clarified that it is useful for diseases that cause onset and progress as a trigger.
[0007]
[Means for Solving the Problems]
The inventors of the present invention have a potent cell growth inhibitory effect on epithelial-derived cells, vascular endothelial cells, lymphocytes and other hematopoietic cells in a drug substance whose active ingredient name is called rabbit extract inoculated with vaccinia virus. , Promoting the production of TGF-β that suppresses the production of cytokines such as inflammatory or cytotoxicity derived from these cells, and also acts to suppress the production or activity of cytokines derived from macrophage cells or Th 1 cells It was found that there is an activity to promote the production of IL-10 and suppress the production of IFN-γ and TNF-α, and the present invention was completed.
[0008]
Rabbit inflammation skin inoculated with vaccinia virus is a known substance described in, for example, page 1710 of the October 1997 edition of the Japan Medicine Collection. Analgesic and sedative, especially as a drug that acts specifically on stressed nerve tissue, the content is expressed in “units” indicating the titer, or substantially equivalent to the “units” It is expressed as “neurotropin unit” and is marketed as a medical drug (hereinafter referred to as “unit”). However, until now, there has been no known regulatory effect on cytokines TGF-β, IL-10, IFN-γ and TNF-α.
[0009]
The dose of the rabbit skin inoculated vaccinia virus inoculated according to the present invention varies depending on the type of disease, the sensitivity of the individual patient, and the level of cytokine to be adjusted, but can be increased or decreased in the range of 1 to 60 units / day. Yes, and can be administered in admixture with a pharmaceutical carrier such as a suitable organic or inorganic solid or liquid excipient. Usually, 3 to 32 units / day, preferably 3.6 to 16 units / day are administered intravenously, subcutaneously, intramuscularly or orally once a day or divided into 2 to 4 times.
[0010]
EXAMPLES The present invention will be described in detail below with reference to examples, but these examples do not limit the scope of the present invention. Unless otherwise specified, the “extract” means the inflammatory skin extract of rabbits inoculated with the vaccinia virus of the present invention.
[0011]
[Example 1]
8-15 weeks old (C57BL / 6 X DBA / 2) F 1 female mice were given a single intraperitoneal injection of 12.5 units / kg of vaccinia virus inoculated rabbit inflammation skin extract (extract) of the present invention. In some cases and when administered intraperitoneally every day for 3 days, the mice were bled 24 hours after administration and serum was collected. A control group of mice was administered physiological saline for injection in the same volume as the administered extract. Use 3 mice in each group. Spleens were collected from the same mice from which the serum was collected, and the total RNA was immediately extracted and purified by a conventional method and stored at −80 ° C. to prepare a sample for reverse transcription reaction-polymerase chain reaction (RT-PCR). TGF-β1 gene-specific downstream primer was added to 1 μg of each mouse spleen RNA, reverse transcriptase was allowed to act to synthesize cDNA, upstream primer was further added, and cDNA was amplified using thermostable DNA synthase. . The cDNA of each sample was fractionated by 2% agar gel electrophoresis, and the concentration of a 525 base pair band was measured with a densitometer. Similarly, the glyceraldehyde-3-phosphate dehydrogenase (G3PDH) gene was synthesized from the RNA of each sample as an internal standard by reverse transcription reaction, and then the cDNA was amplified. After measuring the concentration of the 983 base pair G3PDH band fractionated by agar gel electrophoresis with a densitometer, the concentration ratio of the TGF-β 1 band to the G3PDH band was calculated for each sample.
[0012]
As a result, the TGF-β 1 band of each sample fractionated by 2% agar gel electrophoresis showed a darker band in the cDNA product group of the extract-administered group than in the control group. TGF-beta 1 gene transcription is promoted. The average value of the concentration ratio of TGF-β 1 band and G3PDH band by densitometer measurement is about 0.9 for the extract-administered group, about 0.7 for the control group, and the average value of the extract-administered group is The value was higher than the average value of the control group (FIG. 1). Repeated peritoneal administration experiment of the same extract again at different times, and intraperitoneal administration of vaccinia virus-inoculated rabbit inflammation skin extract promoted TGF-β 1 gene transcription statistically significantly (p <0.01) (Fig. 2).
[0013]
[Figure 1]
[0014]
[Figure 2]
[0015]
[Example 2]
Two (C57BL / 6 X DBA / 2) F 1 female mice aged 8 to 15 weeks were given 12.5 units / kg of rabbit skin inoculated vaccinia virus-inoculated rabbit extract of the present invention (extract) per day. It was administered intraperitoneally every day for 3 days. After 24 hours, the spleen was collected and the cells were cultured for 48 hours. Two mice in the control group were similarly administered with the same volume of physiological saline for injection as that of the administered extract. The culture supernatant was recovered, and the biological activity of TGF-β was determined as mink lung fibroblast growth inhibitory activity. The sample from one animal was quantified twice, and the average value was calculated. Alternatively, after collecting the spleen, spleen cells were isolated and cultured with concanavalin A for 24 hours, and then the culture supernatant was collected. The amount of active TGF-β protein in the spleen cell culture supernatant was determined by sandwich solid-phase enzyme immunization (ELISA) assay.
[0016]
It was confirmed that administration of the extract not only promotes TGF-β gene transcription but also promotes TGF-β protein production. Since this biological activity measurement method detects the total TGF-β activity of TGF-β 1 , TGF-β 2 , and TGF-β 3 , TGF-β not only for TGF-β 1 but also for the administration of the extract is used. 2, the effect of the TGF-β 3 production also means that it is possible to estimate. Calibration curve showing the correlation between the biological activity and TGF-beta protein content was made using a genetic recombinant human TGF-beta 1. For the measurement of active TGF-β, the culture supernatant is used as it is as a sample, and the total TGF-β is measured by treating the culture supernatant with hydrochloric acid to convert latent TGF-β to the active form. It was. In the extract administration group of this experiment, active TGF-β was 907,7 pg / ml and total TGF-β was 1226.4 pg / ml, whereas in the control group, 135.5 pg / ml, It was 639.6 pg / ml (FIG. 3). Thus, administration of the extract promoted both active and latent TGF-β production from splenocytes.
[0017]
[Fig. 3]
[0018]
[Example 3]
8 to 15-week-old (C57BL / 6 X DBA / 2) F 1 female mice are injected once intraperitoneally with 25 units / kg of vaccinia virus-inoculated rabbit inflammatory skin extract (extract) of the present invention. At about the same time, 6.25 mg / kg of concanavalin A or physiological saline for injection was injected intradermally. On the third day after administration, blood was collected from each mouse, and serum was separated to prepare a test sample. As a result of measuring the amount of active TGF-β 1 protein in serum using recombinant human TGF-β 1 for preparing a calibration curve using the sandwich ELISA method, The active TGF-β 1 in the serum of the extract-administered group is 8.76 ng / ml, the control group is 7.12 ng / ml, and the concanavalin A-administered group is the active TGF-β in the serum of the extract-administered mouse. 1 was 7.86 ng / ml, and 7.05 ng / ml in the control group (FIG. 4). Thus, administration of the extract resulted in a statistically significant increase in serum TGF-β level regardless of the presence or absence of concanavalin A co-administration (p <0.05). Concanavalin A co-administration did not affect serum TGF-β levels.
[0019]
[Fig. 4]
[0020]
[Example 4]
8-15 weeks old (C57BL / 6 X DBA / 2) F 1 female mice are treated with 12.5 units / kg of vaccinia virus inoculated rabbit inflammation skin extract (extract) of the present invention once a day for 3 days. After continuous intraperitoneal administration, the spleen was collected 24 hours later, immediately extracted and purified with total RNA by a conventional method, stored at −80 ° C., and used as a RT-PCR sample. A control group of mice was administered the same volume of physiological saline for injection as the extract. Use 3 mice in each group. An IL-10 gene-specific downstream primer was added to 1 μg of each mouse spleen RNA, and a reverse transcriptase was allowed to act to synthesize cDNA. Then, an upstream primer was further added, and the cDNA was amplified using a thermostable DNA synthase. Similarly, for the G3PDH gene as an internal standard from the total RNA of each sample, cDNA was synthesized by reverse transcription reaction and then amplified. The cDNA of each sample was fractionated by 2% agar gel electrophoresis, and the concentration of the 421 base pair band of IL-10 was measured with a densitometer. In the 2% agar gel electrophoresis photograph of the cDNA product after RT-PCR reaction of IL-10 and G3PDH, the cDNA product of the extract-administered group (lanes 4, 5, 6) is more control group (lanes 1, 2). 3) A darker band was shown. After measuring the band concentration with a densitometer, the concentrations of IL-10 band and G3PDH band for each sample were compared. As a result, when the band concentration ratio average value of the control group was 1.0, the average of the extract administration group The value was 2.62, and IL-10 gene transcription was significantly (p <0.01) promoted by the extract administration (FIG. 5).
[0021]
[Figure 5]
[0022]
[Example 5]
Experiment for confirming the promotion of IL-10 gene transcription by single administration of 12.5 units / kg of rabbit skin inoculated vaccinia virus-inoculated rabbit extract of the present invention
Using two mice in each group, RT-PCR was performed on IL-10 gene from 1 μg of spleen mRNA in the same manner as in the experiment of Example 4 except that the number of administrations was single administration. As a result of comparison with the physiological saline control group, when the concentration ratio of IL-10 and G3PDH band in the untreated group was 1.0, the physiological saline-administered group 1.31 and the extract-administered group 2.29 three times Although the degree was lower than that of administration, a tendency to promote IL-10 gene transcription was observed even after single administration (FIG. 6).
[0023]
[Fig. 6]
[0024]
[Example 6]
Vaccinia virus inoculated rabbit inflammation skin extract (extract) 10, 25, 50 units / kg of the present invention was intraperitoneally administered 5 times in 3 days to (C57BL / 6 X DBA / 2) F 1 female mice, After 16 hours, the spleen was collected, and the spleen cells were isolated and cultured in the presence of 3.0 g / ml of concanavalin A for 43 hours, and IL-10 in the culture supernatant was quantified by sandwich ELISA. One group uses 5 animals. For the preparation of the calibration curve, genetically modified mouse IL-10 was used. The amount of IL-10 protein contained in the spleen cell culture supernatant of the extract administration group was 129.0 pg / ml in the 10 unit / kg administration group, 131.1 pg / ml in the 25 unit / kg administration group, 50 units / kg. In the kg administration group, the concentration was 163.6 pg / ml, and in any group administered with the extract, the IL-10 protein concentration in the spleen cell culture supernatant was 107.5 pg / ml in the untreated group, or physiological saline for injection was administered. Compared with the IL-10 protein concentration of the group 112.3 pg / ml, it significantly increased (p <0.05 or p <0.01) (FIG. 7).
[0025]
[Fig. 7]
[0026]
[Example 7]
(C57BL / 6 X DBA / 2) F 1 female mouse was inoculated with the vaccinia virus inoculated rabbit inflammation skin extract (extract) 6.25, 12.5 units / kg once a day for 3 days. It was administered intraperitoneally. The mice in the control group were similarly administered with physiological saline for injection and dexamethasone 2 mg / kg / dose as the suppression positive control group. About 24 hours after the last administration, the spleen was collected, and the spleen cells were cultured in the presence of concanavalin A 2.5 μg / ml for 24 hours, and IFN-γ in the culture supernatant was quantified by sandwich ELISA. For the preparation of the calibration curve, genetically modified mouse IFN-γ was used. Administration of the extract reduced the amount of IFN-γ produced by mouse spleen cells in a dose-dependent manner, with 12.5 units / kg up to 1.94 ng / ml, which is similar to 1.78 ng / ml in the dexamethasone administration group. -The amount of γ production was suppressed (Fig. 8).
[0027]
[Fig. 8]
[0028]
[Example 8]
(C57BL / 6 X DBA / 2) F 1 female mice were intraperitoneally administered once daily for 3 days with 12.5 units / kg of vaccinia virus-inoculated rabbit inflammation skin extract (extract) of the present invention. . The mice in the control group were similarly administered with physiological saline for injection and dexamethasone 2 mg / kg as the suppression positive control group. About 24 hours after the last administration, the spleen was collected, and the spleen cells were cultured in the presence of E. coli-derived endotoxin (E. coli 026: B6) 10 / μg / ml for 2 hours, and TNF-α in the culture supernatant was removed. Quantification was performed by sandwich ELISA. For the preparation of the calibration curve, genetically modified mouse TNF-α was used. TNF-α production of splenocytes in the extract administration group was suppressed to the same extent as in the dexamethasone administration group (FIG. 9).
[0029]
FIG. 9
[Brief description of the drawings]
1 is a band graph showing the concentration ratio of after electrophoresis of the cDNA of TGF-beta 1 and G3PDH after RT-PCR reaction in Example 1.
[2] The same experiment as in Example 1 with experiments conducted at different time, which is a graph showing a band density ratio after electrophoresis of TGF-beta 1 and G3PDH.
3 is a graph showing active TGF-β activity and total TGF-β activity in the spleen cell culture supernatant of mice in Example 2. FIG.
4 is a graph showing the results of measuring the active TGF-beta 1 in mouse serum was measured by sandwich ELISA in Example 3.
5 is a graph showing the concentration ratio of bands after electrophoresis of IL-10 and G3PDH cDNA after RT-PCR reaction in Example 4. FIG.
FIG. 6 is a graph showing the concentration ratio of IL-10 and G3PDH bands after electrophoresis in experiments conducted at different dates and times similar to those in Example 4.
7 is a graph showing the results of measuring the amount of IL-10 protein in the concanavalin A-stimulated culture supernatant of mouse spleen cells in Example 6 by sandwich ELISA. FIG.
FIG. 8 is a graph showing the results of measuring the IFN-γ concentration in the concanavalin A-stimulated culture supernatant of mouse splenocytes in Example 7 by sandwich ELISA measurement.
FIG. 9 is a graph showing the results of measuring the TNF-α concentration in the E. coli-derived endotoxin-stimulated culture supernatant of mouse spleen cells in Example 8 by sandwich ELISA measurement.

Claims (1)

ワクシニアウイルス接種家兎皮膚抽出液を有効成分とし、腫瘍壊死因子およびインターフェロン−γの産生亢進を伴う網膜剥離、炎症性腸疾患および穿孔性腹膜炎からなる群のいずれかの疾患を治療するためのサイトカイン調節剤。 And rabbits inoculated with vaccinia virus skin extract as an active ingredient, tumor瘍壊Shiinko and retinal detachment with enhanced production of interferon-gamma, for the treatment of any disease of the group consisting of inflammatory bowel disease and perforation peritonitis Cytokine regulators.
JP27289399A 1999-08-20 1999-08-20 Cytokine regulator Expired - Fee Related JP4612924B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP27289399A JP4612924B2 (en) 1999-08-20 1999-08-20 Cytokine regulator

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP27289399A JP4612924B2 (en) 1999-08-20 1999-08-20 Cytokine regulator

Publications (2)

Publication Number Publication Date
JP2001058950A JP2001058950A (en) 2001-03-06
JP4612924B2 true JP4612924B2 (en) 2011-01-12

Family

ID=17520237

Family Applications (1)

Application Number Title Priority Date Filing Date
JP27289399A Expired - Fee Related JP4612924B2 (en) 1999-08-20 1999-08-20 Cytokine regulator

Country Status (1)

Country Link
JP (1) JP4612924B2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442546B2 (en) * 2002-03-15 2008-10-28 The Regents Of The University Of Michigan Method of modulating inflammatory response
TWI342778B (en) 2002-10-31 2011-06-01 Nippon Zoki Pharmaceutical Co Therapeutic agent for fibromyalgia
CN1207005C (en) * 2002-10-31 2005-06-22 威世药业(如皋)有限公司 Rabbit skin containing bioactive substance and its use
WO2005105133A2 (en) * 2004-04-23 2005-11-10 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
TWI406664B (en) * 2006-03-30 2013-09-01 Univ Kyoto Agent increasing the production of thioredoxin
WO2008063639A2 (en) 2006-11-21 2008-05-29 Massachusetts Eye And Ear Infirmary Compositions and methods for preserving cells of the eye
CN101732348B (en) * 2008-11-11 2015-01-14 威世药业(如皋)有限公司 Application of varicella vaccine inflammation induced rabbit fur extractive in preparing medicaments for treating acute cerebrovascular diseases
JP6803678B2 (en) * 2015-04-09 2020-12-23 日本臓器製薬株式会社 Herpes zoster keratitis amelioration or treatment
JP6169807B2 (en) * 2015-05-29 2017-07-26 日本臓器製薬株式会社 Pluripotent stem cell migration promoter

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3852786B2 (en) * 1995-04-25 2006-12-06 日本臓器製薬株式会社 Bone atrophy improving agent
JP4033936B2 (en) * 1997-01-08 2008-01-16 日本臓器製薬株式会社 Nitric oxide production inhibitor

Also Published As

Publication number Publication date
JP2001058950A (en) 2001-03-06

Similar Documents

Publication Publication Date Title
Babu et al. Role of tumor necrosis factor alpha in asthma
Selby et al. Tumour necrosis factor in man: clinical and biological observations
Girndt et al. Production of interleukin-6, tumor necrosis factor α and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients
JP5907970B2 (en) Application of interleukin-22 in the treatment of viral hepatitis
Luedke et al. Interferon-gamma overcomes glucocorticoid suppression of cachectin/tumor necrosis factor biosynthesis by murine macrophages.
Bernaudin et al. Demonstration by in situ hybridization of dissimilar IL-1 beta gene expression in human alveolar macrophages and blood monocytes in response to lipopolysaccharide.
EP3849586B1 (en) Sclerotium rolfsii lectin for treatment of inflammatory diseases
US11147815B2 (en) Compositions and methods for treating diseases associated with uncontrolled inflammatory responses
CN117187096A (en) Coli strain for improving intestinal barrier function and application thereof
EP1487491A2 (en) Novel of cytokine inhibitors
JP4612924B2 (en) Cytokine regulator
Ramakrishna et al. Tyrosine kinase 2 inhibitors in autoimmune diseases
CN112843222A (en) Application of ANKRD22 protein in preparing product for treating or delaying autoimmune diseases
Bettex-Galland et al. Neutrophil-activating peptide-1/interleukin-8 detection in human urine during acute bladder inflammation caused by transurethral resection of superficial cancer and bacillus Calmette-Guérin administration
JP4381495B2 (en) MCP-1 receptor antagonist comprising organic germanium compound as active ingredient, and preventive or therapeutic agent for inflammatory disease and organ disorder involving MCP-1
JPH02209812A (en) Pharmaceutical composition for treating psoriasis
US20180235912A1 (en) Pharmaceutical composition for preventing or treating autoimmune diseases comprising thiourea derivative
Silvera et al. Synthesis of interleukin-1 receptor antagonist by Thy-1+ and Thy-1-murine lung fibroblast subsets
Furse et al. Increased monocyte TNF‐α message stability contributes to trauma patients' increased TNF production
CN116549449A (en) Application of pirfenidone as medicine for preventing and treating inflammatory bowel disease intestinal fibrosis
KR20120052201A (en) Use of benzydamine in the treatment of p40-dependent diseases
US20250152668A1 (en) Protein for treatment of inflammatory diseases
CN109602735A (en) Drugs for preventing and/or treating intestinal diseases and application of α-cyano-4-hydroxycinnamic acid
JP2019534325A (en) Composition for preventing or treating psoriasis containing a monoacetyldiacylglycerol compound
US7655237B2 (en) Use of soluble CD14 for treatment of type 2 diabetes mellitus

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060609

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20060609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100113

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20100721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100825

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100929

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101018

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131022

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees